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We recently reported that diﬀerent puriﬁcation methods of recombinant adeno-associated virus type 2 (rAAV2) aﬀect the
transduction characteristics following subretinal injection. In this study, we examined the roles of contaminant proteins from the
HEK-293 cells and helper adenovirus, inactivation of helper adenovirus and cell stress induced by DNA-damaging agents in rAAV-
mediated retinal transduction. Our results showed that contaminating factors/proteins resulting from the helper E1 deleted ade-
novirus are possibly responsible for eﬃcient RPE transduction. Future studies of these factors will undoubtedly lead to development
of new therapeutic approaches to PR- and RPE-speciﬁc retinal diseases.
 2003 Elsevier Ltd. All rights reserved.
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Retinal degeneration (RD) is a family of inherited
retinal diseases that lead to vision loss (Rattner, Sun, &
Nathans, 1999). Recent advances in molecular genetics
have led to the mapping of more than 130 loci and
cloning of more than 70 genes associated with inherited
RDs (http://www.sph.uth.tmc.edu/RetNet/). A minority
of the inherited RDs are characterized by photoreceptor
(PR)-speciﬁc gene defects and at least seven genes ex-
pressed in retinal pigment epithelium (RPE) are associ-
ated with inherited RDs, thus making PR and RPE the
principal cell targets for gene therapy in the eye (http://
www.sph.uth.tmc.edu/RetNet/).
Recombinant adeno-associated virus (rAAV) has
emerged as a very promising vector for gene therapy
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doi:10.1016/j.visres.2003.09.032dividing cells with long-term and stable transgene ex-
pression and reduced or lack of immunogenicity (Ac-
land et al., 2001; Ali et al., 2000; LaVail et al., 2000;
Liang et al., 2001; McGee Sanftner, Abel, Hauswirth, &
Flannery, 2001; Sarra et al., 2001). Major eﬀorts have
been expended in improving the techniques to produce,
purify and concentrate rAAV vectors, aiming to eﬃ-
ciently deliver transgenes into target cells. To date,
rAAV type 2 (rAAV2) is the serotype that has been the
most extensively tested in retinal gene transfer. How-
ever, interpretation of previous data on PR and RPE
transduction has been complicated by wide variations in
terms of purity and concentration of rAAV2 stocks and
conﬂicting results showed varying transduction charac-
teristics after subretinal injection of rAAV2 driven by an
ubiquitous CMV promoter (Bennett, Duan, Engelhardt,
& Maguire, 1997; Bennett et al., 1999; Grant, Pon-
nazhagan, Wang, Srivastava, & Li, 1997; Green, Ren-
dahl, Zhou, Ladner, & Coyne, 2001; McGee Sanftner
et al., 2001; Rolling et al., 1999; Sarra et al., 2002).
Factors aﬀecting the transduction characteristics of
rAAV are poorly understood. Certain promoters can
restrict the activity of transgene expression to certain cell
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promoter and interphotoreceptor retinoid binding pro-
tein promoter direct transgene expression exclusively in
PR, but not in any other retinal cell types (Flannery
et al., 1997; Jomary et al., 1999). In contrast, RPE65
promoter predominantly drives transgene expression in
RPE (Boulanger, Liu, Henningsgaard, Yu, & Redmond,
2000; Schwesinger et al., 2001). More recently, it has
become increasingly evident that diﬀerent serotypes of
rAAV transduce RPE and PR variably and that ex-
change of surface proteins between diﬀerent serotypes
changes transduction characteristics (Auricchio et al.,
2001; Rabinowitz et al., 2002; Yang et al., 2002).
The transduction characteristics by rAAV2 appear
variable among diﬀerent species of animals in previous
studies (Bennett, Anand, Acland, & Maguire, 2000;
Bennett et al., 1997, 1999; Narfstrom et al., 2003; Sarra
et al., 2002; Shen et al., 2003). Recently we reported that
diﬀerent methods of production and puriﬁcation of
rAAV2 had a dramatic impact on patterns of transgene
expression following subretinal injection in rodents
(Shen et al., 2003). In this study, we continued that line
to examine several factors that could aﬀect the trans-
duction characteristics of rAAV2. These factors include
(i) cellular extract from HEK293 cells, (ii) impurity of
rAAV2 from the processes of co-infection of HEK293
cells with E1-defective adenovirus and puriﬁcation by
one-step CsCl2 density gradient centrifugation (CsCl2-
rAAV2), (iii) active helper adenovirus particles and (iv)
cell genotoxic stress by DNA-damaging agents.2. Materials and methods
2.1. Generation and puriﬁcation of recombinant adeno-
associated virus type 2
rAAV used in this study was based on AAV type 2
carrying an enhanced green ﬂuorescent protein (GFP)
gene driven by a cytomegalovirus (CMV) promoter
(AAV2.CMV.GFP). A total of three batches of
AAV2.CMV.GFP were used in this study (Table 1).
Batch A was produced in HEK293 cells with a triple-
transfection system in the presence of a helper adeno-
viral plasmid to provide the essential helper virus genes.
Batch A was puriﬁed by iodixanol (Optiprep, Nycomed,
Oslo, Norway) density step gradient centrifugation fol-
lowed by heparin column chromatography (HiTrap
heparin, Amersham Pharmacia, Uppsala, Sweden)
(heparin-rAAV2) and thus the chance of adenovirus
contamination is rare or can be considered as free of
adenovirus contamination. Batch B was produced in
HEK293 cells using an E1-deleted helper adenovirus to
generate the rAAV2 particles as reported previously
(Lai, Rolling, Baker, & Rakoczy, 2001; Lai et al., 2002).
Batch B was puriﬁed in the same way as batch A. BatchC was produced in the same way as batch B but was
puriﬁed by one-step cesium chloride density gradient
centrifugation (CsCl2-rAAV2). All the three batches of
rAAV2 stocks were dialyzed against PBS and heat-
treated at 56 C for 30 min to inactivate contaminating
adenovirus. The titers of rAAV2 were determined in
triplicate by infecting HEK293 cells with diﬀerent dilu-
tions of vector stocks. The number of cells showing GFP
ﬂuorescence was counted and virus titers were reported
in transduction units/ml (tu/ml). The levels of wild-type
AAV2 contamination were determined by Southern
analysis and they were between 0.01% and 0.1% in all
batches of rAAV2. Titers of viruses used in this study
ranged from 5.0 · 107 to 2.0 · 1010 tu/ml (Table 2).
2.2. SDS-PAGE assessment of CsCl2-rAAV2 and hepa-
rin-rAAV2
Ten microliters of heparin-rAAV2 (batch B, Table 1)
and CsCl2-rAAV2 (batch C, Table 1) were boiled in
SDS-PAGE reducing buﬀer for 5 min and then elec-
trophoresed on an 8.5% polyacrylamide gel. The gel was
then silver-stained according to the protocol by Scopes
and Smith (1998). Brieﬂy, the gel was ﬁxed (50%
methanol, 10% acetic acid), destained (5% methanol, 7%
acetic acid) and covered in 10% glutaraldehyde before
washing thoroughly with water. The gel was soaked in 5
lg/ml dithiothreitol before incubating in 0.1% silver
nitrate solution, washed and then agitated in carbonate
developing solution (0.0185% formaldehyde solution,
3% sodium carbonate) until the desired level of staining
was achieved. Staining was stopped by adding 2.3 M
citric acid.
2.3. Preparation of crude lysate from HEK293 cells
HEK293 cells (5.0 · 106 cells) were washed with PBS
and harvested by trypsinization. The harvested cells
were further washed twice and centrifuged. The resulting
cell pellet was re-suspended in 1.0 ml PBS and disrupted
by sonication according to the literature (Rolling &
Samulski, 1995). Cellular debris was eliminated by
centrifugation at 1500g for 5 min and the crude lysate
from HEK293 cells (CL293) was stored at )80 C for
further use.
2.4. Subretinal administration of rAAV2
Normal congenic non-pigmented RCS-rdyþ rats of
8–10 weeks age were used in this study. rAAV2 was
delivered into the subretinal space in 2.0 ll solution as
described previously (Shen et al., 2003). The following
strategies were used to evaluate the eﬀects of possible
contaminants in rAAV preparations on the transduction
characteristics (Table 2)––(1) supplement of the crude
lysate fromHEK293 cells (CL293) into heparin-rAAV2 at
Table 1
Batches of rAAV2.CMV.GFP generated and puriﬁed by diﬀerent methods for subretinal injection in the rat
Batch Generation Puriﬁcation Contamination of Ad fac-
tors/proteins
A Co-transfection with a helper
adenoviral plasmid
Iodixanol density gradient centrifugation
plus heparin column chromatography
Rare or free
B Co-infection with an E1-deleted
helper adenovirus
Iodixanol density gradient centrifugation
plus heparin column chromatography
Low
C Co-infection with an E1-deleted
helper adenovirus
One CsCl2 density gradient centrifugation
only
High
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rAAV2mixed with CsCl2-rAAV2 in various proportions:
(i) 100% heparin-rAAV2, (ii) 3/4 volume of heparin-
rAAV2, (iii) 3/4 volume of heparin-rAAV2 plus 1/4 vol-
ume of CsCl2-rAAV2, (iv) 1/4 volume of CsCl2-rAAV2
and (v) 100% CsCl2-rAAV2; (3) twice heat inactivation
(56 C, 30 min) of the possible contamination of helper
adenovirus in CsCl2-rAAV2 stocks prior to subretinal
injection; (4) subretinal injection of heparin-rAAV2 in the
presence of DNA-damaging agents: (i) heparin-rAAV2
with 4mMhydroxyurea (HU), (ii) heparin-rAAV2with 3
lM trichostatin A (ISA) and (iii) heparin-rAAV2 with 4
mM HU and 3 lM TSA and (iv) intravitreal delivery of
40 mM HU and 30 lM TSA at 12 weeks after subretinal
injection of heparin-rAAV2 (Table 2).2.5. Detection of GFP ﬂuorescence by fundus ﬂuorescence
photography and determination of transduced cell types
by ﬂuorescence microscopy
GFP expressionwasmonitored by fundus ﬂuorescence
photography as early as 2 weeks post-injection and was
periodically repeated for 10–14 months post-injection as
described previously (Rolling et al., 1999). Results wereFig. 1. Silver-stained SDS-PAGE gel showing diﬀerent protein patterns betw
bands corresponding to the AAV capsid proteins VP1, VP2 and VP3 are inassessed by calculating the percentage of GFP positive
eyes detected by ﬂuorescence fundus photography and
grading transduced area and ﬂuorescence intensity on a
scale of 0–4 as follows: score 0¼ negative, 1¼ isolated
patches withweakGFP ﬂuorescence, 2¼ isolated patches
with moderate GFP ﬂuorescence, 3¼ isolated patches of
strong GFP ﬂuorescence and 4¼ evenly distributed
strong GFP ﬂuorescence. To determine the predominant
cell types transduced by rAAV2 following subretinal in-
jection, eyes were enucleated and examined by ﬂuores-
cence microscopy at termination using ﬂat-mounted
neuroretinas and RPE–choroid–sclera complexes as well
as cryosections as described previously (Lai, Shen, Con-
stable, & Rakoczy, 1999; Shen et al., 2003).3. Results
3.1. Protein contaminants in CsCl2-rAAV2
The purities of heparin-rAAV and CsCl2-rAAV2 viral
stocks were compared using SDS-PAGE electrophoresis.
Fig. 1 shows that the viral stock of heparin-rAAV (batch
B) contained three proteins with sizes correspondingeen CsCl2-rAAV (lane 1) and heparin-rAAV (lane 2). The three protein
dicated.
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In comparison, CsCl2-rAAV (batch C) had a signiﬁcant
amount of contaminating proteins (lane 1). The identities
of these contaminating proteins are unclear, but may
represent proteins from HEK293 cells and the helper
adenovirus.
3.2. Sonicated crude lysate of HEK293 cells does not
change the transduction characteristics of heparin-rAAV2
To investigate whether the predominant RPE trans-
duction by CsCl2-rAAV2 is related to protein contami-Fig. 2. The impact of sonicated crude lysate of HEK293 cells (CL293) on the
(batch A, see Table 1) after subretinal injection. (A) Percentage of the eyes sho
involve anyone expressing GFP signal as detected by ﬂuorescence fundus pho
injection of heparin-rAAV with and without supplement of CL293 (see Sectio
point post-injection. h-rAAV¼heparin-rAAV.
Fig. 3. Transduction characteristics by heparin-rAAV (batch A, see Table 1)
12 weeks post-injection by fundus ﬂuorescence photography (A and B) and by
rAAV (batch A) alone. (B and D) heparin-rAAV (batch A) with the additio
protein residues from the CL293. RPE¼ retinal pigment epithelium, ONL¼
D) · 50, respectively.nants from HEK293 cells, heparin-rAAV2 free of
adenovirus contamination (batch A, Table 1) was mixed
with HEK293 cellular crude lysate (CL293) at a ratio of
4:1 (volume) for subretinal injection. In general, the
onset and transduction intensity by heparin-rAAV2
with or without the presence of CL293 were not dra-
matically changed when observed by fundus ﬂuores-
cence photography from 2 to 12 weeks post-injection
(Fig. 2). Although GFP ﬂuorescence with the addition
of CL293 seemed to be slightly stronger compared with
that without CL293 (Fig. 3A and B), results of semi-
quantiﬁcation did not show statistical signiﬁcance be-onset and intensity of transgene expression mediated by heparin-rAAV
wing GFP ﬂuorescence from 2 to 12 weeks post-injection. Positive eyes
tography. (B) Semi-quantiﬁcation of GFP ﬂuorescence after subretinal
n 2 for grading scales). The data represent 6–8 eyes/group at each time
with or without addition of CL293. (A–D) GFP ﬂuorescence detected at
ﬂuorescence microscopy of cryosections (C and D). (A and C) heparin-
n of CL293. The yellowish signal in (B) and (D) may be due to foreign
outer nuclear layer. Original magniﬁcations: (A and B) · 6, (C and
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addition of CL293, the transduction characteristics in
RPE and PR by heparin-rAAV (batch A) have not been
changed when determined by ﬂuorescence microscopy.
The GFP ﬂuorescence almost exclusively localized to
PR in the neural retina (Fig. 3C and D), although a few
RPE cells were occasionally transduced (Table 2).3.3. Twice inactivation of helper adenovirus does not
change the transduction characteristics of CsCl2-rAAV2
In consideration of a possibility that contamination
of active helper adenovirus might contribute to the ef-
ﬁcient RPE transduction by CsCl2-rAAV2, two CsCl2-
rAAV2 stocks were twice heated at 56 C for 30 min
prior to subretinal injection (Table 2). Results showed
that twice inactivation of active helper adenovirus did
not change the transduction characteristics of CsCl2-
rAAV2 (Table 2).3.4. Introduction of cell stress by DNA-damaging agents
does not change the transduction characteristics of
heparin-rAAV2
It has been shown that rAAV2 vectors preferentially
transduce cells in the S phase and that DNA-damaging
agents HU and TSA increased the transduction eﬃ-
ciency in non-dividing cells (Chen & Townes, 2000;
Russell, Alexander, & Miller, 1995; Russell, Miller, &
Alexander, 1994). In this study, PR and RPE were also
exposed to heparin-rAAV2 at the presence of HU and
TSA, either alone or in combination (Table 2). The used
concentrations have been shown to enhance transduc-Fig. 4. The impact of supplement of rAAV-CsCl2 on the onset of transgene
eyes include anyone expressing GFP signal as detected by ﬂuorescence fundus
listed in Table 2. The data represent 6–12 eyes/group at each time point. h-rtion eﬃciency but without aﬀecting cell viability or
proliferative potential in vitro (Chen & Townes, 2000;
Russell et al., 1995). From 2 to 8 weeks post-injection in
the present study, GFP ﬂuorescence was not detectable
by fundus ﬂuorescence photography in any groups of
animals due to the signiﬁcant decrease in the titer of
heparin-rAAV2 (1.6 · 107 tu/ml, Table 2). Fluorescence
microscopy revealed that treatment with HU and TSA
slightly increased the transduction eﬃciency in PR but
did not change the transduction characteristics of hep-
arin-rAAV2. In all groups, GFP ﬂuorescence was
mainly localized to PR although scattered and weak
RPE transduction was visible (Table 2). In addition,
intravitreal injection of 40 mM HU with 30 lM TSA at
12 weeks post-subretinal injection did not change the
cell target speciﬁcity of heparin-rAAV2 (Table 2).3.5. Supplement of a small amount of CsCl2-rAAV2 into
heparin-rAAV2 dramatically increases the transduction
eﬃciency in RPE
To investigate whether adenoviral contaminants in
CsCl2-rAAV2 contribute to the predominant RPE
transduction, a small amount of CsCl2-rAAV2 was
supplemented into heparin-rAAV2 at a ratio of 1:3
(volume) for subretinal injection (Table 2). In all groups,
GFP ﬂuorescence was detectable from 2 weeks post-
injection by fundus ﬂuorescence photography. At 2weeks
post-injection, however, more eyes showed GFP ﬂuo-
rescence in the groups infected with CsCl2-rAAV2 when
compared with those receiving heparin-rAAV2 only
(Fig. 4). The percentages of GFP positive eyes in the
groups receiving 100% heparin-rAAV2 (5.0 · 108 tu/ml),expression mediated by heparin-rAAV (batch B, see Table 2). Positive
photography from 2 to 12 weeks post-injection. The titers of rAAV are
AAV¼heparin-rAAV.
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(5.0 · 107 tu/ml) and 100% CsCl2-rAAV2 (2.0 · 108 tu/
ml), were 25%, 25%, 37.5% and 100%, respectively (Fig.
4). In general, the onset and intensity of transgene ex-
pression in CsCl2-rAAV2 injected eyes were faster and
stronger compared with those receiving heparin-rAAV2,
even when a lower titer was used (Figs. 4–6). With the
same puriﬁcation method, rAAV2-mediated transgene
expression was both time- and titer-dependent and rel-
atively stable transgene expression was observed from 4
to 8 weeks post-injection (Figs. 4–6).
Surprisingly, with the supplement of 1/4 volume of
CsCl2-rAAV2 into 3/4 volume of heparin-rAAV2 (ﬁnal
titer: 4.25 · 108 tu/ml), more eyes (58%) showed GFP
ﬂuorescence at 2 weeks post-injection compared to only
25% in the group receiving 100% heparin-rAAV2
(5.0 · 108 tu/ml) (Fig. 4). The intensity of transgene ex-
pression at 2 and 4 weeks post-injection was also sig-
niﬁcantly increased by the supplement of small amount
of CsCl2-rAAV2 (Figs. 5 and 6, P < 0:05).
Using ﬂat-mounted neural retinas, RPE–choroid–
scleral complexes and cryosections obtained from whole
eyeballs, the transduced cell types by diﬀerent rAAV2
stocks were determined by ﬂuorescence microscopy.
Consistent with previous data (Shen et al., 2003), sub-
retinal injection of CsCl2-rAAV2 predominantly trans-
duced RPE and heparin rAAV2 mainly transduced PR
(Table 2). However, supplement of 1/4 volume of CsCl2-
rAAV2 into 3/4 volume of heparin-rAAV2 (ﬁnal titer:Fig. 5. The impact of supplement of rAAV-CsCl2 on the intensity of transge
ﬂuorescence was graded by analyzing the images obtained from fundus ﬂuore
grading scales). The data represent 6–12 eyes/group at each time point. The
rAAV-CsCl2 vs 100% h-rAAV; (y) P < 0:05, 100% rAAV-CsCl2 vs 100% h-rA
all by unpaired t test. h-rAAV¼heparin-rAAV.4.25 · 108 tu/ml) dramatically increased RPE transduc-
tion, showing strong and evenly distributed GFP ﬂuo-
rescence in the RPE cells (Table 2). This was very much
diﬀerent from the transduction characteristics of 100%
heparin-rAAV2 (5.0 · 108 tu/ml) or 3/4 heparin-rAAV2
(3.75 · 108 tu/ml), but much more similar to the patterns
of transgene expression mediated by 100% CsCl2-
rAAV2 (2.0 · 108 tu/ml) (Table 2).4. Discussion
Traditional production of rAAV requires both host
cell factors and co-infection with helper adenovirus or
herpes virus for the infection cycle. This study examined
three batches of rAAV2 viral stocks that were produced
and puriﬁed by diﬀerent methods. Batch A was pro-
duced with a triple-transfection system in the presence of
a helper adenoviral plasmid to provide the essential
helper virus genes (Xiao, Li, & Samulski, 1998). This
batch of rAAV was puriﬁed by iodixanol density step
gradient centrifugation followed by heparin column
chromatography. The puriﬁcation method by heparin
column chromatography takes advantage of the binding
property of rAAV2 to heparan sulfate proteoglycans
(Summerford & Samulski, 1998). With this method of
production and puriﬁcation, the possibility of contami-
nation by adenovirus factors/proteins is rare. Batch B
was produced using an E1-deleted helper adenovirusne expression mediated by heparin-rAAV (batch B, see Table 2). GFP
scence photography from 2 to 12 weeks post-injection (see Section 2 for
titers of rAAV are listed in Table 2. () P < 0:05, 3/4 h-rAAV+1/4
AV; and (z) P < 0:05, 3/4 h-rAAV+1/4 rAAV-CsCl2 vs 100% h-rAAV;
Fig. 6. Representative photographs showing the patterns of GFP expression after 8 weeks of subretinal injection of h-rAAV (A–C), rAAV-CsCl2 (E–
F), or co-infection with h-rAAV and rAAV-CsCl2 (D). Titers of rAAV: (A) 5.0· 108 tu/ml, (B) 3.75· 108 tu/ml, (C) 2.5· 108 tu/ml, (D) 4.25· 108 tu/
ml, (E) 5.0· 107 tu/ml and (F) 2.0 · 108 tu/ml, respectively. Note stronger and much more granular GFP ﬂuorescence in (D) and (F) compared to (A).
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with a helper adenovirus plasmid. Although batch B was
puriﬁed in the same way as batch A, it is still possible
that low levels of heparin-binding proteins resulting
from contaminating helper E1 deleted adenovirus were
co-puriﬁed with rAAV2 particles. Batch C was produced
in the same way as batch B but puriﬁed by one-step
cesium chloride (CsCl2) density gradient centrifugation
only. The conventional puriﬁcation protocol by CsCl2
density gradient centrifugation inevitably resulted in
impure quality of rAAV compared with batch B of
rAAV2.
A previous study reported that cellular factors from
sonicated extract of HEK293 cells increased rAAV2-
mediated transduction eﬃciency in cells that were nor-
mally poorly transduced (Tenenbaum et al., 1999). One
of the important characterizations of HEK293 cells is
the presence of adenovirus E1 gene product in this
transformed cell line. Therefore, contaminating factorsresulting from HEK293 cells could involve adenovirus
E1 gene product and other HEK293 cellular proteins. In
the present study, we have tested whether cellular pro-
teins extracted from HEK293 cells could change the
transduction characteristics of heparin-rAAV2 (batch
A). Our results demonstrated that supplementing
HEK293 cellular extracts into heparin-rAAV2 did not
change the transduction characteristics although the
intensity of GFP ﬂuorescence in the neural retina was
slightly increased at 2 weeks post-injection. Thus, the
sole protein contaminants from HEK293 cells are not
responsible for eﬃcient RPE transduction by CsCl2-
rAAV2. However, a possibility still exists that HEK293
cellular proteins could act cooperatively with the prod-
ucts from helper adenoviral genes, such the adenovirus
E1 region (that also exists in HEK293 cells) acts coop-
eratively with the adenovirus E4 ORF6 region thus en-
hancing rAAV2-mediated gene transduction in RPE
(Trahair, Alexander, Rowe, & Smythe, 2000).
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tems but puriﬁed in the same way, analysis of the
transduction eﬃciency of batches A and B allows direct
comparison of contaminating proteins resulting from
helper adenovirus plasmid and helper E1 deleted ade-
novirus (batch A vs batch B). Results in Table 2 show
that a much higher titer of batch A (2.0 · 1010 tu/ml) did
not eﬃciently transduce RPE but a much lower titer of
batch B (5.0 · 108 tu/ml) increased the transduction ef-
ﬁciency in RPE, suggesting that the use of helper E1
deleted adenovirus during rAAV2 production contrib-
uted to certain levels of RPE transduction. Batches B
and C of rAAV2 were produced exactly in the same way
but puriﬁed by diﬀerent methods. As batch B of hepa-
rin-AAV2 was supposed to be much purer than batch C
of CsCl2-AAV2, direct comparison of the transduction
characteristics between batches B and C could reveal the
eﬀect of diﬀerent levels of contaminating adenoviral
proteins. The results showed less eﬃcient transduction
in RPE and stronger transduction in PR with higher
titers of heparin-AAV2 (5.0 · 108, 3.75 · 108 tu/ml)
compared to CsCl2-AAV2 (2.0 · 108 tu/ml). A previous
study has shown that a 110-KDa protein, which has
been conﬁrmed to be the human nucleolin, was co-Table 2
Transduction characteristics determined by ﬂuorescence microscopy followin
Treatment Eye no. (n) Titre (tu/ml)
(1) Supplement of cellular extracts from 293 cells(CL293)
100% heparin-rAAV2 (A)a 8 2.0 · 1010
4/5 heparin-rAAV2
(A)+ 1/5 CL293
6 1.6 · 1010
(2) Dilution and co-infection
100% heparin-rAAV2 (B) 8 5.0 · 108
3/4 heparin-rAAV2 (B) 8 3.75· 108
3/4 heparin-rAAV2
(B) + 1/4 CsCl2-rAAV2 (C)
12 4.25· 108
1/4 CsCl2-rAAV2 (C) 8 5.0 · 107
100% CsCl2-rAAV2 (C) 6 2.0 · 108
(3) Twice heat inactivation of helper adenovirus
CsCl2-rAAV2 (C) 4 2.0 · 108
4 1.0 · 109
(4) Treatment with DNA-damaging agentsb
1/2 heparin-rAAV2
(B) + 1/2 PBSc
8 1.6 · 107
1/2 heparin-rAAV2
(B) + 1/2 HU
8 1.6 · 107
1/2 heparin-rAAV2
(B) + 1/2 TSA
6 1.6 · 107
1/2 heparin-rAAV2
(B) + 1/4 HU+1/4 TSA
6 1.6 · 107
a (A)–(C)¼ batches of rAAV (also see Table 1).
bGFP ﬂuorescence was not detectable by fundus ﬂuorescence photograp
samples and cryosections.
c Four eyes further received intravitreal injection of HU (40 mM) plus TS
were followed up for another 8 weeks. Graded GFP ﬂuorescence: score 0¼n
patches with moderate GFP ﬂuorescence, 3¼ isolated patches of strong GFpuriﬁed with AAV2 after CsCl2 density gradient cen-
trifugation and nucleolin speciﬁcally binds to AAV2
(Qiu & Brown, 1999). In the present study, CsCl2-AAV2
preparation probably resulted in the co-puriﬁcation of
factor(s) that are possibly in favor of RPE transduction,
or inhibitors of PR transduction, therefore allowing
CsCl2-AAV2 particles to transduce RPE more eﬃ-
ciently. Purer heparin-AAV2 may have a stronger tro-
pism for PR and it is also possible that further
puriﬁcation of CsCl2-AAV2 removed the factors in
favor of RPE tropism or the inhibitors of PR trans-
duction, thus allowing heparin-AAV2 to transduce PR
more eﬃciently and with less eﬃciency in RPE.
The precise identiﬁcation of contaminating factors/
proteins in CsCl2-rAAV2 is time-consuming because of
the complexity of contaminating proteins from helper
E1 deleted adenovirus. Therefore, direct investigation of
the roles of puriﬁed factors/proteins from helper E1
deleted adenovirus is currently diﬃcult in the present
study. Our further studies showed that the addition of
5.0 · 107 tu/ml of CsCl2-rAAV2 (batch C) into 3.75 · 108
tu/ml of haparin-rAAV2 (batch B) resulting in a ﬁnal
titer of 4.25 · 108 tu/ml rAAV2, dramatically increased
the transduction eﬃciency in RPE when compared withg subretinal injection of rAAV2 various preparations in the rat
Transduced cell types
PR RPE
++++ +
++++ +
+++ ++
++ ++
++ ++++
+ +
++ +++
++ +++
++ ++++
+ +
++ +
++ +
+++ +
hy but was observed by ﬂuorescence microscopy using ﬂat-mounted
A (30 lM) in 2.0 ll solution at 12 weeks post-subretinal injection and
egative, 1¼ isolated patches with weak GFP ﬂuorescence, 2¼ isolated
P ﬂuorescence and 4¼ evenly distributed strong GFP ﬂuorescence.
W.-Y. Shen et al. / Vision Research 44 (2004) 339–348 347that using sole haparin-rAAV2 (5.0 · 108 tu/ml of batch
B). This further conﬁrmed our hypothesis that con-
taminating adenoviral proteins in CsCl2-rAAV2 are re-
sponsible for eﬃcient RPE transduction. Eﬃcient gene
transfer requires virus attachment and binding, inter-
nalization, migration to the nucleus, decapsidation,
conversion to double-stranded DNA and gene expres-
sion. It is unclear how supplement of small amounts of
CsCl2-rAAV2 improved the transduction eﬃciency in
RPE. The present experiment does not permit the deter-
mination on which cellular processing the CsCl2-rAAV2
acted. Recent data have shown that the adenovirus E4
ORF6 gene product and treatment of target cells with
genotoxic stress can dramatically enhance the trans-
duction eﬃciency by rAAV2 in normally poorly trans-
duced cell lines (Chen & Townes, 2000; Russell et al.,
1994, 1995). These eﬀects have been correlated with an
increased proportion of single-stranded DNA genomes
undergoing second-strand synthesis (Ferrari, Samulski,
Shenk, & Samulski, 1996; Trahair et al., 2000). To
clarify whether the eﬃcient RPE transduction by CsCl2-
rAAV2 is related to cell genotoxic stress induced by the
impurity of virus preparations, heparin-rAAV2 was also
delivered into the subretinal space in the presence of
DNA-damaging agents HU and TSA. HU and TSA
have been shown to stimulate the conversion of viral
single strand DNA to transcriptionally active double-
stranded DNA, thus enhancing the transduction eﬃ-
ciency of rAAV2 in vitro (Chen & Townes, 2000; Russell
et al., 1994). In the present study, treatment with HU
and TSA increased the intensity of GFP expression in
PR but did not enhance the transduction eﬃciency in
RPE. Similarly, the transduction eﬃciency in RPE by
heparin-rAAV2 could not be enhanced by later intra-
vitreal injection of HU and TSA. Our results also
showed that twice heat-treatment to inactivate helper
adenovirus did not aﬀect the pattern of transgene ex-
pression by CsCl2-rAAV2. This rules out the possibility
that active helper adenovirus particles contribute to ef-
ﬁcient RPE transduction but it does not exclude the
roles of contaminated adenoviral proteins because
adenoviral proteins were still present and may be re-
sponsible for RPE tropism of CsCl2-rAAV2. In general,
our results suggest that the poor transduction of RPE by
heparin-rAAV2 is not due to the rate-limiting synthesis
of double-strand DNA, but most possibly, could be
associated with the poor binding and/or internalization
of heparin-rAAV2 onto RPE during the cellular steps of
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